ライフサイエンスコーパス: aminoglycoside

1 within 4 d after treatment with a synthetic aminoglycoside.

2 (6')lb genes, resulting in susceptibility to aminoglycosides.

3 on of vancomycin without coadministration of aminoglycosides.

4 considering the frequent coadministration of aminoglycosides.

5 e same dying hair cell following exposure to aminoglycosides.

6 the presence of nonsense suppressors such as aminoglycosides.

7 All but one infant also received aminoglycosides.

8 reduced the electrophysiological response to aminoglycosides.

9 hB gene leads to decreased susceptibility to aminoglycosides.

10 er modifications on glucopyranosyl ring I of aminoglycosides.

11 site of the ribosome, the region targeted by aminoglycosides.

12 the vulnerability to noise, salicylate, and aminoglycosides.

13 udy were susceptible to fluoroquinolones and aminoglycosides.

14 l other 4,6-disubstituted 2-deoxystreptamine aminoglycosides.

15 rains when the MRSA isolate was resistant to aminoglycosides.

16 that was susceptible to fluoroquinolones and aminoglycosides.

17 acin [a fluoroquinolone], and gentamicin [an aminoglycoside]).

18 .7% for those containing monotherapy with an aminoglycoside (13/60) (P = .008), and was mostly attrib

19 ibiotic tolerance (TolC efflux pump and AadA aminoglycoside 3-adenyltransferase).

20 The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 p

21 erobacteriaceae that were not susceptible to aminoglycosides (78.8% vs. 68.6%) and Enterobacteriaceae

22 that was susceptible to fluoroquinolones and aminoglycosides, a short regimen was noninferior to a lo

23 el class of potent antibacterial amphiphilic aminoglycosides (AAGs) with significant improved activit

24 aryotic ribosomes and of overcoming the rare aminoglycoside acetyltransferase (3)-IV class of aminogl

25 The bacterial enzyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside p

26 In these analyses, the aminoglycosides act as receptors, while RNA structures l

27 These results indicate that aminoglycoside actions must be framed in the context of

28 y accepted that membrane voltage potentiates aminoglycoside activity, which is ascribed to voltage-de

29 whose upregulation causes resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN) in Myco

30 There is compelling evidence that aminoglycoside (AG) antibiotics can induce the mammalian

31 y structures of the ribosome of a pathogenic aminoglycoside (AG)-resistant Pseudomonas aeruginosa str

32 value of a number of antibiotics, including aminoglycosides, against intracellular pathogenic bacter

33 Aminoglycosides (AGs) are broad-spectrum antibiotics tha

34 Aminoglycosides (AGs) are broad-spectrum antibiotics use

35 Aminoglycosides (AGs) constitute a major family of poten

36 Cationic amphiphiles derived from aminoglycosides (AGs) have been shown to exhibit enhance

37 for drug-resistant tuberculosis (DR-TB) with aminoglycosides (AGs) in resource-limited settings often

38 river samples predominantly belonging to the aminoglycoside and beta-lactam resistance classes.

39 , cell membrane function, detoxification and aminoglycoside and beta-lactam resistance.

40 our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a pr

41 patients is well tolerated, combined use of aminoglycoside and the non-toxic adjuvant L-arginine as

42 to oxidative stress, increased resistance to aminoglycosides and cationic antimicrobial peptides, and

43 ey are generally resistant to metronidazole, aminoglycosides and ciprofloxacin with L. acidophilus be

44 he response of Escherichia coli treated with aminoglycosides and discovered that the bactericidal act

45 ward decreasing microbial resistance against aminoglycosides and imipenem also was detected.

46 By different mechanisms, aminoglycosides and inhibition of sulphate transport cau

47 beneficial for reducing hearing loss due to aminoglycosides and overstimulation.

48 wide manner, we treated mammalian cells with aminoglycosides and performed ribosome profiling.

49 Aminoglycosides and tetracyclines substantially improve

50 Aminoglycosides and tetracyclines were used more commonl

51 otransducer channel and interactions between aminoglycosides and the bacterial ribosome.

52 ostatic interaction energies between various aminoglycosides and their binding sites correlate with e

53 We studied six pairs of aminoglycosides and their corresponding ribosylated deri

54 tions and its per-ring contributions between aminoglycosides and their primary rRNA binding site.

55 litude of electrostatic interactions between aminoglycosides and their rRNA targets to introduce amin

56 rapy with broad-spectrum beta-lactams and/or aminoglycosides and/or fluoroquinolones was started.

57 linical settings (such as cephalosporins and aminoglycosides) and can acquire resistance to vancomyci

58 fections, but it also reduced cephalosporin, aminoglycoside, and vancomycin exposure and reduced the

59 ines, macrolides-lincosamides, sulfonamides, aminoglycosides, and beta-lactams were quantified using

60 he other containing both sulfonamides, three aminoglycosides, and tetracycline.

61 ck confers substantial otoprotection against aminoglycoside- and cisplatin-induced hair cell death.

62 boxamide, 1 (ORC-001), as protective against aminoglycoside antibiotic (AGA)-induced hair cell death.

63 ANG's nuclear translocation by neomycin, an aminoglycoside antibiotic (not G418-neomicin), resulted

64 555A>G predisposes to hearing loss following aminoglycoside antibiotic exposure in an idiosyncratic d

65 The aminoglycoside antibiotic hygromycin B (Hyg) inhibits pr

66 xy alkyl modification of a readily available aminoglycoside antibiotic increases the inherent antibac

67 mprove survival of hair cells exposed to the aminoglycoside antibiotic neomycin, whereas inhibition o

68 A series of 20 4'-O-glycosides of the aminoglycoside antibiotic paromomycin were synthesized a

69 Gentamicin is a potent broad-spectrum aminoglycoside antibiotic whose use is hampered by ototo

70 Paromomycin (PAR), a broad-spectrum aminoglycoside antibiotic, has been shown in recent year

71 saccharide Pel, which protects bacteria from aminoglycoside antibiotics and contributes to biofilm ar

72 The aminoglycoside antibiotics antagonized and down-regulate

73 Although aminoglycoside antibiotics are effective against Gram-ne

74 Aminoglycoside antibiotics are known toxins to cochlear

75 Exposure to aminoglycoside antibiotics can lead to the generation of

76 ue member of the 2-deoxystreptamine class of aminoglycoside antibiotics characterized by a monosubsti

77 Different aminoglycoside antibiotics combined with different sulph

78 the design and development of a new class of aminoglycoside antibiotics culminating in the discovery

79 point for the development of next-generation aminoglycoside antibiotics for the treatment of multidru

80 in that can act synergistically and detoxify aminoglycoside antibiotics highly efficiently.

81 recently showed that vaginal application of aminoglycoside antibiotics induces robust activation of

82 l subunit RNA of the bacterial ribosome, the aminoglycoside antibiotics inhibit protein synthesis, ca

83 Aminoglycoside antibiotics interfere with ribosomal func

84 aration of a series of four analogues of the aminoglycoside antibiotics neomycin and paromomycin is d

85 After destruction of hair cells with aminoglycoside antibiotics or noise, SGNs gradually die.

86 e side effect for many patients treated with aminoglycoside antibiotics or platinum-containing chemot

87 an improved understanding of how amphiphilic aminoglycoside antibiotics that bind to negatively charg

88 ility to fluoroquinolone, cephalosporin, and aminoglycoside antibiotics using disk diffusion assays.

89 d 4,5-disubstituted 2-deoxystreptamine class aminoglycoside antibiotics was predicted and was borne o

90 romising avenue for the development of novel aminoglycoside antibiotics with improved efficacy and re

91 ues, such as hyperosmolarity and presence of aminoglycoside antibiotics, (ii) narrowed their metaboli

92 sh lateral line hair cells after exposure to aminoglycoside antibiotics, a well characterized hair ce

93 on-derived kinase that confers resistance to aminoglycoside antibiotics, in Escherichia coli under se

94 ays a significant role in resistance against aminoglycoside antibiotics, is controlled by a translati

95 An example is aminoglycoside antibiotics, which by binding to ribosoma

96 Clinical use of 2-deoxystreptamine aminoglycoside antibiotics, which target the bacterial r

97 high-level resistance to a broad spectrum of aminoglycoside antibiotics.

98 ts induced on lipid membranes by amphiphilic aminoglycoside antibiotics.

99 fusion system, with decreased resistance to aminoglycoside antibiotics.

100 th ototoxic drugs, including the widely used aminoglycoside antibiotics.

101 ce, to develop a sensor for the detection of aminoglycoside antibiotics.

102 a new paradigm for the development of safer aminoglycoside antibiotics.

103 iosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics.

104 cells resistant to hydrogen peroxide and to aminoglycoside antibiotics.

105 miting factor in the clinical application of aminoglycoside antibiotics.

106 Aminoglycosides are a class of antibiotics that possess

107 Aminoglycosides are a well known antibiotic family used

108 COL7A1, and previous studies have shown that aminoglycosides are able to overcome RDEB PTC mutations

109 Aminoglycosides are antibiotic drugs that act through bi

110 Aminoglycosides are broad-spectrum antibiotics whose mec

111 Aminoglycosides are chemically diverse, broad-spectrum a

112 materials that are enabled by lipid-modified aminoglycosides are demonstrated.

113 Aminoglycosides are mostly known as highly potent, broad

114 Aminoglycosides are potent, broad spectrum, ribosome-tar

115 In the absence of voltage, aminoglycosides are taken into cells and exert bacterios

116 Aminoglycosides are widely used broad-spectrum antibioti

117 odel of voltage-induced death, and separates aminoglycoside bacteriostasis and bactericide in E. coli

118 itro screening of linear polyamine-based and aminoglycoside-based polymer libraries identified severa

119 In contrast, the aminoglycoside-based polymer paromomycin-BGDE, enhanced

120 with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug

121 well as MST markers and resistance genes to aminoglycosides, beta-lactams, and tetracycline.

122 Although aminoglycosides bind helix69 of the bacterial large subu

123 The conformational changes and similar aminoglycoside binding affinities observed for human mit

124 st possible modifications that could enhance aminoglycoside binding affinity.

125 In addition, aminoglycoside binding enhanced conformational stability

126 bility, base stacking, and conformation upon aminoglycoside binding to the human cytoplasmic helix69

127 human mitochondrial and E. coli helix69 upon aminoglycoside binding, as compared with human cytoplasm

128 ncapsulated RI promotes the protection of an aminoglycoside-binding RNA E-AB sensor up to 6 h, enabli

129 at 3.3- to 3.7-A resolution, reveal multiple aminoglycoside-binding sites within the large and small

130 prD3, is responsible for 3'-deoxygenation in aminoglycoside biosynthesis.

131 methyltransferases confer resistance to most aminoglycosides, but discriminating their activity from

132 resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found n

133 translated in the cytoplasm, we showed that aminoglycosides can paradoxically elevate rather than re

134 Here, we show that aminoglycosides cause cytosolic protein misfolding and t

135 the antiplasmid activity of kasugamycin, an aminoglycoside; CGS 15943, a nucleoside analog; and Ro 9

136 Here we show that aminoglycosides chemically related to neomycin-paromomyc

137 strate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lact

138 , Dutch guidelines recommend beta-lactam and aminoglycoside combination therapy or carbapenem monothe

139 When compared with monotherapy, aminoglycoside-containing combination therapy did not de

140 rategies synthesized were monotherapy versus aminoglycoside-containing combination therapy; antipseud

141 ensitizes hair cells to the toxic effects of aminoglycosides, contrasting with current models of exci

142 When GJIC was inhibited during the aminoglycoside damage paradigm, the epithelial repair re

143 the initial epithelial repair process in the aminoglycoside-damaged BP.

144 3',6-Dinonyl neamine is an amphiphilic aminoglycoside derivative active against Pseudomonas aer

145 r rational design of new, and more specific, aminoglycoside derivatives as potential therapeutic agen

146 l structurally related natural and synthetic aminoglycoside derivatives.

147 Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-resistant E

148 Based on the increased aminoglycoside efficiency under alkaline conditions, we

149 Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransduc

150 The distinct impacts of the aminoglycosides examined suggest that their chemical com

151 engers conferred superior protection against aminoglycoside exposure compared with identical, untarge

152 lly inherited hearing loss in the absence of aminoglycoside exposure or any other clinical features (

153 potential to ameliorate the toxic effects of aminoglycoside exposure.

154 Ca(2+) effectors mitigates toxic effects of aminoglycoside exposure.

155 ultiple antibiotics, including beta-lactams, aminoglycosides, fluoroquinolones, and polymyxins.

156 or IAP and the combination of penicillin and aminoglycoside for postnatal treatment.

157 ribosomal A site: Geneticin (G418), a potent aminoglycoside for the treatment of leishmaniasis at a 2

158 of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infecti

159 se of the guanidinylated ligand, but the two aminoglycoside fragments seem to interfere with its acco

160 liver regulates Se metabolism, we tested the aminoglycosides G418 and gentamicin in hepatoma cell lin

161 We found that the aminoglycosides G418 and gentamicin rescued the expressi

162 tive release factors, or the presence of the aminoglycoside gentamicin.

163 Recently, some aminoglycosides have been clinically approved and are cu

164 Aminoglycosides have been proposed as therapies for gene

165 other classes of antibiotic drugs, including aminoglycosides, have become common.

166 in 614 (68%) of 904 cases and resistance to aminoglycosides in 317 (27%) of 1176 cases.

167 ved readthrough small molecule PTC124 and 11 aminoglycosides in a cell culture system on four PTCs re

168 widespread presence severely compromises all aminoglycosides in current clinical practice.

169 arative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown.

170 a hydrogen atom in the catalytic triad of an aminoglycoside inactivating enzyme leads to a thirty-fol

171 fect on irreversible hearing loss induced by aminoglycosides, including gentamicin (GM).

172 We showed that certain aminoglycosides induce rapid plasma membrane permeabiliz

173 asis; however the molecular details by which aminoglycosides induce their deleterious effect on Leish

174 k proteins (HSPs) confers protection against aminoglycoside-induced hair cell death via paracrine sig

175 Ca(2+) homeostasis play an essential role in aminoglycoside-induced hair cell death, and indicate sev

176 ondrial calcium drives ROS generation during aminoglycoside-induced hair cell death.

177 erized a novel otoprotectant working against aminoglycoside-induced hearing loss.

178 eutic effects and support the use of PBM for aminoglycoside-induced hearing loss.

179 vide structural and functional insights into aminoglycoside-induced impacts on the eukaryotic ribosom

180 the hypothesis that rosuvastatin can inhibit aminoglycoside-induced nephrotoxicity in children with C

181 d degradation of nephrin underlies puromycin aminoglycoside-induced podocytopathy and FSGS in vivo.

182 The aminoglycoside-induced readthrough strategy has been uti

183 Better understanding of the origin of aminoglycoside-induced ROS could focus the development o

184 ynamics simulations, we studied how modified aminoglycosides influence the essential freedom of movem

185 We demonstrate that aminoglycosides inhibit protein synthesis in hair cells

186 s into the structural elements important for aminoglycoside inhibitory activities and selectivity for

187 n of kanamycin B converts this antibacterial aminoglycoside into a novel antifungal agent.

188 rs 1 and 3 (eRF1 and eRF3) or by introducing aminoglycosides into the cells.

189 ncorporating two exhaustively guanidinylated aminoglycosides into the receptor library.

190 However, the effectiveness of this aminoglycoside is still limited by its inability to pene

191 cal gentamicin, a mixture of several related aminoglycosides, is a frequently used antibiotic in huma

192 of the 4,6-disubstituted 2-deoxystreptamine aminoglycoside kanamycin B led to improved selectivity f

193 illin and penicillin), quinolone (enoxacin), aminoglycoside (kanamycin and neomycin), and polykeptide

194 The efficiency of aminoglycoside-mediated readthrough depends on the type

195 ay and, thus, represent a potential class of aminoglycoside mimetics.

196 ycosides and their rRNA targets to introduce aminoglycoside modifications that would enhance their bi

197 rous common resistance determinants, be they aminoglycoside modifying enzymes or rRNA methyl transfer

198 ere investigated further for the presence of aminoglycoside-modifying enzyme genes using multiplex PC

199 t discriminating their activity from that of aminoglycoside-modifying enzymes (AMEs) is challenging u

200 s of aminoglycoside resistance including the aminoglycoside-modifying enzymes and the ribosomal methy

201 oglycoside acetyltransferase (3)-IV class of aminoglycoside-modifying enzymes that constitutes the on

202 also partially stabilized the ES, whereas an aminoglycoside molecule that binds RNAs nonspecifically

203 problems, we engineered Pentobra, a peptide-aminoglycoside molecule that has multiple mechanisms of

204 present crystal structures of two different aminoglycoside molecules bound to a model of the Leishma

205 Among those treated with an aminoglycoside (n = 407 [53%]), the case fatality rate w

206 philic 3',6-dialkyl derivatives of the small aminoglycoside neamine as broad spectrum antibacterial a

207 trum antibiotics, or with the gut-restricted aminoglycoside neomycin alone, accelerated phagocyte tur

208 s in cultured podocytes, and a new puromycin aminoglycoside nephropathy model of INF2 transgenic mice

209 ypothesis that rosuvastatin protects against aminoglycoside nephrotoxicity.

210 4'-O-glycosylation blocking the action of 4'-aminoglycoside nucleotidyl transferases by the use of re

211 d acquired resistance to fluoroquinolones or aminoglycosides occurred in 3.3% and 2.3%, respectively.

212 ngs suggest that the interfering activity of aminoglycosides on selenoprotein biosynthesis can be sev

213 tibiotic therapy (beta-lactam plus either an aminoglycoside or a fluoroquinolone) protected against d

214 ta provide an exciting proof-of-concept that aminoglycosides or other readthrough-promoting compounds

215 f concurrent resistance to fluoroquinolones, aminoglycosides, or macrolides (P < .001).

216 therapy with tetracyclines, chloramphenicol, aminoglycosides, or sulfonamides was 1.3%, 1.4%, 7.5%, a

217 In addition to aminoglycosides, other classes of antimicrobials includi

218 ning the role of fractalkine signaling after aminoglycoside ototoxicity or acoustic trauma.

219 r understanding of the mechanisms underlying aminoglycoside ototoxicity remains limited.

220 ts the survival of sensory hair cells during aminoglycoside ototoxicity, a common cause of acquired h

221 therapy was more commonly used in polymyxin/aminoglycoside patients than those who received ceftoloz

222 In applications to an aminoglycoside phosphotransferase [APH(3')-IIIa] and pan

223 zyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside phosphotransferase(2'')-Ia possesses an N

224 (RNA) with basic ligands such as proteins or aminoglycosides play a key role in fundamental biologica

225 We performed a dose-ranging study with the aminoglycoside plazomicin against Pseudomonas aeruginosa

226 Our data indicate that 4'-O-substituted aminoglycosides possess increased selectivity towards ba

227 405 (m(7)G1405) have been identified in both aminoglycoside-producing and clinically drug-resistant p

228 RNA secondary structure motifs utilizing an aminoglycoside receptor library.

229 We demonstrate that arbekacin, an aminoglycoside refractory to most AMEs, can rapidly dete

230 sistance, colistin resistance and high-level aminoglycoside resistance can be transferred together ev

231 wn that fusA1 mutants often display elevated aminoglycoside resistance due to increased expression of

232 f tetracycline, multidrug, erythromycin, and aminoglycoside resistance genes were discovered in these

233 min, bacitracin, vancomycin, beta-lactam and aminoglycoside resistance genes were the top seven most

234 iae that includes two beta-lactamase and two aminoglycoside resistance genes.

235 g center results in exceptionally high-level aminoglycoside resistance in bacteria.

236 ceptible to the most prevalent mechanisms of aminoglycoside resistance including the aminoglycoside-m

237 subspecies and determining the macrolide and aminoglycoside resistance levels of 50 Mycobacterium abs

238 nal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.

239 nd "not cured." Strong biofilm formation and aminoglycoside resistance were associated with a "not-cu

240 , effectively combats multiple mechanisms of aminoglycoside resistance, and minimizes one of the majo

241 ntly lower during SDD compared with SOD; for aminoglycoside resistance, average prevalence was 5.6% (

242 tly overlaps with that of a second family of aminoglycoside resistance-associated 16S rRNA (m(1)A1408

243 al study of 30S substrate recognition by the aminoglycoside resistance-associated 16S rRNA (m(7)G1405

244 ISPR)/Cas9 system, and in vivo selection for aminoglycoside resistance.

245 cluding the extended-spectrum ss-lactam- and aminoglycoside-resistance genes, were identified in the

246 0S recognition by the novel plasmid-mediated aminoglycoside-resistance rRNA methyltransferase A (NpmA

247 new molecular framework for the activity of aminoglycoside-resistance rRNA methyltransferases that m

248 monia model induced by a clinically isolated aminoglycoside resistant strain of P. aeruginosa is deve

249 entions the prevalence of rectal carriage of aminoglycoside-resistant gram-negative bacteria increase

250 ia but a more pronounced gradual increase in aminoglycoside-resistant gram-negative bacteria.

251 n, considered among the least and most toxic aminoglycosides, respectively, reduce auditory cell dama

252 C3'-deoxygenation of aminoglycosides results in their decreased susceptibilit

253 rt to crystallographically derived models of aminoglycoside-ribosome interactions.

254 ructed the aspherical electron density of 12 aminoglycoside-RNA complexes from the atomic parameters

255 s and PCA loading factors revealed trends in aminoglycoside:RNA recognition, including the importance

256 (ethambutol), gyrA (fluoroquinolones), rrs (aminoglycosides), rpsL, rrs and giB (streptomycin) loci.

257 natural or semisynthetic pseudodisaccharide aminoglycoside scaffolds containing an equatorial amine

258 For the pseudodisaccharide aminoglycoside scaffolds neamine and nebramine, ribosyla

259 Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no

260 addition to stimulating readthrough of PTCs, aminoglycosides stimulate readthrough of normal terminat

261 several chaperone proteins upregulated under aminoglycoside stress, show that antibiotics with the sa

262 Treatment with aminoglycosides such as streptomycin or gentamicin is ef

263 AAS and aerobic systems especially reduced aminoglycoside, tetracycline, and beta-lactam ARG levels

264 ugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and beta-lactams have be

265 were a priori classified into high-efficacy (aminoglycosides, tetracyclines, fluoroquinolones, sulfon

266 have identified highly charged compounds or aminoglycosides that commonly have modest selectivity.

267 tions in the drug-binding site, resulting in aminoglycosides that interact poorly with the drug-bindi

268 st on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ fai

269 d minimizes one of the major side effects of aminoglycoside therapy.

270 rifampicin, fluoroquinolones and injectable aminoglycosides, they would be suitable for treating man

271 The ability of a particular aminoglycoside to inhibit protein synthesis and to activ

272 The propensity of aminoglycosides to induce miscoding errors that suppress

273 e strong and differential binding ability of aminoglycosides to RNA structures can be used to classif

274 ination with selection for resistance to the aminoglycoside tobramycin, the aac(6')-Ie/aph(2'')-Ia ge

275 le vectors, derived from naturally occurring aminoglycoside tobramycin, was prepared using improved s

276 However, aminoglycoside toxicity will likely prevent widespread c

277 binding event is important to understanding aminoglycoside toxicity.

278 tated survival but did not promote growth of aminoglycoside-treated bacteria.

279 mal A site in control, ataluren-treated, and aminoglycoside-treated cells.

280 Focused analyses with aminoglycoside-treated patients are needed next to evalu

281 Both aminoglycoside treatment and acoustic overstimulation le

282 in mammalian hair cells in-vivo triggered by aminoglycoside treatment.

283 ncy (aOR = 2.4; 95% CI = 1.0-5.8; P = .046), aminoglycoside use (aOR = 4.7; 95% CI = 2.2-9.8; P < .00

284 e; 95% confidence interval [CI], 0.99-1.21), aminoglycoside use (OR, 2.33; 95% CI, 1.17-4.57), resist

285 with higher mortality than streptomycin, and aminoglycoside use was linked to higher mortality than f

286 a glycopeptide (27/284) (with or without an aminoglycoside) vs 21.7% for those containing monotherap

287 ber needed to harm with AKI with a polymyxin/aminoglycoside was 4.

288 ical gatifloxacin, prophylaxis using topical aminoglycoside was ineffective (OR, 1.97; CI, 1.17-3.31)

289 nt trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16).

290 Tetracyclines, chloramphenicol, and aminoglycosides were associated with the lowest case fat

291 In both media, aminoglycosides were more efficacious in the 3-D cell mo

292 (rifampin, isoniazid, fluoroquinolones, and aminoglycosides) were analyzed for markers.

293 dDC sensitizes cells to oxidative stress and aminoglycosides, which can be suppressed by eamA overexp

294 Gentamicin is an aminoglycoside widely used in treatments of, in particul

295 Plazomicin is an aminoglycoside with bactericidal activity against multid

296 ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical

297 Our work demonstrates that equipping aminoglycosides with selective membrane activity is a vi

298 and cocaethylene with similar affinities and aminoglycosides with similar or higher affinities in a m

299 veal the interactions of distinct classes of aminoglycosides with the 80S eukaryotic ribosome.

300 ra combines the potent ribosomal activity of aminoglycosides with the bacteria-selective membrane-per

301 However, the sites of interaction of aminoglycosides with the eukaryotic ribosome and their m